Targeting integrin αvβ3 with indomethacin inhibits patient‐derived xenograft tumour growth and recurrence in oesophageal squamous cell carcinoma
F Liu, Q Wu, W Han, K Laster, Y Hu… - Clinical and …, 2021 - Wiley Online Library
Rationale A high risk of post‐operative recurrence contributes to the poor prognosis and low
survival rate of oesophageal squamous cell carcinoma (ESCC) patients. Increasing …
survival rate of oesophageal squamous cell carcinoma (ESCC) patients. Increasing …
[HTML][HTML] ITGAV targeting as a therapeutic approach for treatment of metastatic breast cancer
IWY Cheuk, MT Siu, JCW Ho, J Chen… - American journal of …, 2020 - ncbi.nlm.nih.gov
During tumorigenesis and metastasis, integrins regulate localization and activity of
proteolytic enzymes that remodel the extracellular matrix. Previous studies have …
proteolytic enzymes that remodel the extracellular matrix. Previous studies have …
Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression
M Kemper, A Schiecke, H Maar, S Nikulin… - Journal of Experimental …, 2021 - Springer
Abstract Background Mesothelial E-and P-selectins substantially mediate the intraperitoneal
spread of Pancreatic ductal adenocarcinoma (PDA) cells in xenograft models. In the …
spread of Pancreatic ductal adenocarcinoma (PDA) cells in xenograft models. In the …
Integrin subunit alpha V promotes growth, migration, and invasion of gastric cancer cells
H Wang, H Chen, Z Jiang, Y Lin, X Wang… - … -Research and Practice, 2019 - Elsevier
Integrin subunit alpha V (ITGAV), a member of integrin family of extracellular matrix
receptors, is involved in many types of cancer. In this study, the expression levels, clinical …
receptors, is involved in many types of cancer. In this study, the expression levels, clinical …
Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival
H Loeser, M Scholz, H Fuchs, A Essakly… - Scientific reports, 2020 - nature.com
Valid biomarkers for a better prognostic prediction of the clinical course in esophageal
adenocarcinoma (EAC) are still not implemented. Integrin alpha V (ITGAV), a …
adenocarcinoma (EAC) are still not implemented. Integrin alpha V (ITGAV), a …
Ilex hainanensis Merr targets ITGAV to suppress the proliferation and metastasis of osteosarcoma cells
Y Pei, YY Zhang, K Zheng, GN Shang… - OncoTargets and …, 2019 - Taylor & Francis
Background Osteosarcoma (OS) is the most common primary malignant bone tumor. Hence,
there is an urgent need to identify effective and safe therapeutic agents against OS. It has …
there is an urgent need to identify effective and safe therapeutic agents against OS. It has …
The clinical significance of integrin subunit alpha V in cancers: from small cell lung carcinoma to pan-cancer
YL Tang, GS Li, DM Li, D Tang, JZ Huang… - BMC Pulmonary …, 2022 - Springer
Background Little is known about the relationship between integrin subunit alpha V (ITGAV)
and cancers, including small cell lung cancer (SCLC). Methods Using large sample size …
and cancers, including small cell lung cancer (SCLC). Methods Using large sample size …
Role of the αv-integrin subunit in cell proliferation, apoptosis and tumor metastasis of laryngeal and hypopharyngeal squamous cell carcinomas: a clinical and in vitro …
JG Lu, YN Sun, C Wang, DJ Jin, M Liu - European Archives of Oto-Rhino …, 2009 - Springer
The objective of this study was to investigate the role of αv-integrin subunit (ITGAV, CD51) in
invasion and metastasis of the laryngeal and hypopharyngeal squamous cell carcinomas …
invasion and metastasis of the laryngeal and hypopharyngeal squamous cell carcinomas …
ITGA2 overexpression promotes esophageal squamous cell carcinoma aggression via FAK/AKT signaling pathway
W Huang, J Zhu, H Shi, Q Wu, C Zhang - OncoTargets and therapy, 2021 - Taylor & Francis
Background Integrin alpha 2 (ITGA2) is highly expressed in various cancers. ITGA2 up
regulation promotes tumor proliferation, invasion, migration, and angiogenesis and ITGA2 is …
regulation promotes tumor proliferation, invasion, migration, and angiogenesis and ITGA2 is …
Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model
G Wu, L Li, M Liu, C Chen, G Wang, Z Jiang… - Cancer cell …, 2022 - Springer
Background Pancreatic cancer is one of the most aggressive malignancies without effective
targeted therapies. MUC1 has emerged as a potential common target for cancer therapy …
targeted therapies. MUC1 has emerged as a potential common target for cancer therapy …